NovoCure (NVCR) Current Assets (2014 - 2026)

NovoCure's Current Assets history runs 13 years deep, the most recent figure standing at $631.7 million for Q1 2026.

• In Q1 2026, Current Assets fell 42.01% year-over-year to $631.7 million; the TTM figure through Mar 2026 stood at $631.7 million (down 42.01% YoY), while the FY2025 annual figure was $646.7 million, down 41.56% from the prior year.
• Current Assets came in at $631.7 million for Q1 2026 at NovoCure, down from $646.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $1.2 billion in Q3 2025 to a low of $631.7 million in Q1 2026.
• A 5-year average of $1.0 billion and a median of $1.1 billion in 2023 frame the typical range for Current Assets.
• Across the five-year window, Current Assets rose 9.55% in 2025 and slumped 42.01% in 2026, its largest moves.
• NovoCure's Current Assets stood at $1.1 billion in 2022, then dropped by 6.94% to $1.0 billion in 2023, then gained by 6.98% to $1.1 billion in 2024, then plunged by 41.56% to $646.7 million in 2025, then dropped by 2.33% to $631.7 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $631.7 million, $646.7 million, and $1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison